If you have been reading about GHRH analog and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-06-10. Numbers and descriptions here follow the published literature rather than marketing material.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized white powder | Supplied as a freeze-dried solid for research use |
| Molecular weight | Approximately 3,647 Da (DAC form) | Lower for the variant lacking the albumin-binding moiety |
| Solubility | Soluble in water and aqueous buffer | Typically dissolved in sterile or bacteriostatic water |
| Typical storage temperature | −20 °C or below | Dry powder, desiccated and protected from light |
| Common analytical method | Reversed-phase HPLC with mass spectrometry | Used for purity estimation and identity confirmation |
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Maapliv is a medication used to treat an acute decompensation episode (sudden worsening) of maple syrup urine disease. Maple syrup urine disease is an inherited disorder in which the body is unable to break down certain building blocks of protein known as branched-chain amino acids, including leucine, isoleucine and valine. As a result, these amino acids build up in the body, including in the brain, where leucine in particular can lead to brain damage. Maapliv is for use in people who cannot receive BCAA-free amino acids by mouth or via a feeding tube. Maapliv contains the amino acids L-alanine, L-arginine, L-aspartic acid, L-cysteine hydrochloride monodhydrate, L-glutamic acid, glycine, L-histidine, L-lysine, L-methionine, L-phenylalanine, L-proline, L-serine, taurine, L-threonine, L-tryptophan, and L-tyrosine. Maapliv is indicated for the treatment of maple syrup urine disease presenting with an acute decompensation episode in people from birth who are not eligible for an oral and enteral branched- chain amino acids free (BCAA- free) formulation. Maapliv was authorized for medical use in the European Union in July 2025.
The numbers 1.930 and 0.537 are phenomenological; these specific values provide a fairly good fit to the data. The product Re√fD (called the "friction Reynolds number") can be considered, like the Reynolds number, to be a (dimensionless) parameter of the flow: at fixed values of Re√fD, the friction factor is also fixed. In the Kármán–Prandtl resistance equation, fD can be expressed in closed form as an analytic function of Re through the use of the Lambert W function:
Before the establishment of the State of Israel in 1948, the Druze lived in the Galilee and Mount Carmel, either in exclusively Druze villages or in villages mixed with Christians, where they had coexisted for centuries. Historically, the relationship between the Druze and their Christian neighbors was better compared to their relationship with their Muslim neighbors in neighboring villages. According to historian Ilan Pappé, during the 1948 Arab–Israeli War, in villages partly inhabited by Druze, Christians were generally exempt from expulsion. According to Pappé, in 1948, Israeli military rulers gathered Christians in the centers of several villages in the Galilee region, planning to deport them. However, Druze village leaders intervened, insisting that all Christians remain in their homes. They utilized all their influence and resources to ensure that the Christian residents could stay. The Galilean village of Rameh, with a Christian majority, was not displaced because of its large Druze population. While the "divide and rule" policy succeeded with the Druze, who were promised immunity, weapons, and privileges, by the Zionist militias, the Palestinian Christian communities were less "cooperative". Israeli Druze and Muslims have comparable socio-economic standards when compared to their wealthier and more educated Israeli Christian counterparts.
=== Critical Path Initiative === The Critical Path Initiative is the FDA's effort to stimulate and facilitate a national effort to modernize the sciences through which FDA-regulated products are developed, evaluated, and manufactured. The Initiative was launched in March 2004, with the release of a report entitled Innovation/Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products.
== History == Polystyrene was discovered in 1839 by Eduard Simon, an apothecary from Berlin. From storax, the resin of the Oriental sweetgum tree Liquidambar orientalis, he distilled an oily substance that he named styrol, now called styrene. Several days later, Simon found that it had thickened into a jelly, now known to have been a polymer, that he dubbed styrol oxide ("Styroloxyd") because he presumed that it had resulted from oxidation (styrene oxide is a distinct compound). By 1845 the Jamaican-born chemist John Buddle Blyth and the German chemist August Wilhelm von Hofmann showed that the same transformation of styrol took place in the absence of oxygen. They called the product "meta styrol"; analysis showed that it was chemically identical to Simon's Styroloxyd. In 1866 Marcellin Berthelot correctly identified the formation of meta styrol/Styroloxyd from styrol as a polymerisation process. About 80 years later it was realized that heating of styrol starts a chain reaction that produces macromolecules, following the thesis of German organic chemist Hermann Staudinger (1881–1965). This eventually led to the substance's receiving its present name, polystyrene. The company I. G. Farben began manufacturing polystyrene in Ludwigshafen about 1931, hoping it would be a suitable replacement for die-cast zinc in many applications. Success was achieved when they developed a reactor vessel that extruded polystyrene through a heated tube and cutter, producing polystyrene in pellet form.
Sources: en.wikipedia.org
==== Blood ==== The three species of vampire bat strictly feed on animal blood (hematophagy); the common vampire bat feeds on mammals, while the hairy-legged (Diphylla ecaudata) and white-winged vampire bats (Diaemus youngi) feed on birds. Vampire bats target sleeping prey and can sense deep breathing. They cut through and peel the animal's skin with their teeth and lap up the blood with their tongues, which have grooves on the underside adapted to this purpose. Certain substances in the saliva keep the blood flowing.
Reflecting different national usages, cunt is described as "an unpleasant or stupid person" in the Compact Oxford English Dictionary, whereas the Merriam-Webster has a usage of the term as "usually disparaging and obscene: woman", noting that it is used in the United States as "an offensive way to refer to a woman". Random House defines it as "a despicable, contemptible or foolish man". Some feminists of the 1970s sought to eliminate disparaging terms such as cunt. Twat is widely used as a derogatory epithet, especially in British English, referring to a person considered obnoxious or stupid. Pussy can indicate "cowardice or weakness", and "the human vulva or vagina" or by extension "sexual intercourse with a woman". In English, the use of the word pussy to refer to women is considered derogatory or demeaning, treating people as sexual objects.
{\displaystyle {\begin{cases}{\ce {^{244}_{96}Cm ->[{\ce {(\alpha,n)}}] ^{247}_{98}Cf ->[\epsilon][3.11 \ {\ce {h}}] ^{247}_{97}Bk}}\\{\ce {^{244}_{96}Cm ->[{\ce {(\alpha,p)}}] ^{247}_{97}Bk}}\end{cases}}}
== History == Evidence emerged by the end of the 1970s that the newly discovered proton pump (H+/K+ ATPase) in the secretory membrane of the parietal cell was the final step in acid secretion. Literature from anaesthetic screenings led attention to the potential antiviral compound pyridylthioacetamide which after further examination pointed the focus on an anti-secretory compound with unknown mechanisms of action called timoprazole. Timoprazole is a pyridylmethylsulfinyl benzimidazole and appealed due to its simple chemical structure and its surprisingly high level of anti-secretory activity. Optimization of substituted benzimidazoles and their antisecretory effects were studied on the newly discovered proton pump to obtain higher pKa values of the pyridine, thereby facilitating accumulation within the parietal cell and increasing the rate of acid-mediated conversion to the active mediate. As a result of such optimization the first proton pump inhibiting drug, omeprazole, was released on the market. Other PPIs like lansoprazole and pantoprazole would follow in its footsteps, claiming their share of a flourishing market, after their own course of development.
Sources: en.wikipedia.org
=== American Public Health Association === Inhorn was also involved in the American Public Health Association, the largest organization of public health professionals in the United States. One of the APHA's roles involved developing methodological publications for environmental laboratories, such as Standard Methods for the Examination of Water and Wastewater. Through its Committee on Laboratory Standards and Practices, the APHA developed clinical laboratory books, such as Diagnostic Procedures for Bacterial, Mycotic, and Rickettsial Diseases. In 1971, CLASP determined that a comprehensive book on quality assurance would be useful for laboratory personnel faced with new CLIA guidelines. A task force was established with Inhorn serving as chair, and a meeting was held at CDC in March 1974 to determine the outline of a book consisting of 5 general chapters on QA and 15 chapters on specific health sciences. The book, called Quality Assurance Practices for Health Laboratories, was published in 1978, with Inhorn serving as editor. Inhorn continued to work as the medical director of the WSLH until he retired from UW in 1998 as professor of Pathology and Laboratory Medicine and Preventive Medicine. During the last 20 years of his career and the 10 years after he retired, Inhorn continued to do research and development work in the field of QA. During these decades, major changes were being implemented in the public health laboratory world. For example, it was recognized that QA was necessary in specimen handling and data reporting, as well as in laboratory performance.
== Contraindications == As with all FDA-approved antidepressants it carries a black-box warning about the potential of an increase in suicidal thoughts or behaviour in children, adolescents and young adults under the age of 25. Its use is also advised against in individuals with known hypersensitivities to either amoxapine or other ingredients in its oral formulations. Its use is also recommended against in the following disease states:
=== Structure-activity relationship === Hydrocortisone, or 17-hydroxycorticosterone, is under the class of glucocorticoids, which are steroids synthesized in the adrenal cortex of the kidneys. In order to illustrate its glucocorticoid activity, the A ring of hydrocortisone has a keto group in the 3rd carbon and a double bond between the 4th and 5th carbon. For the C ring of the compound, the 11th carbon has a beta hydroxyl substitution, which is also necessary for the drug to demonstrate glucocorticoid effects.
where Δπ = 1 or −1 corresponds to no parity change or parity change, respectively. The special case of a transition between isobaric analogue states, where the structure of the final state is very similar to the structure of the initial state, is referred to as "superallowed" for beta decay, and proceeds very quickly. The following table lists the ΔJ and Δπ values for the first few values of L:
The discovery of nuclear fission occurred in 1938 in the buildings of the Kaiser Wilhelm Society for Chemistry, today part of the Free University of Berlin, following over four decades of work on the science of radioactivity and the elaboration of new nuclear physics that described the components of atoms. In 1911, Ernest Rutherford proposed a model of the atom in which a very small, dense and positively charged nucleus of protons was surrounded by orbiting, negatively charged electrons (the Rutherford model). Niels Bohr improved upon this in 1913 by reconciling the quantum behavior of electrons (the Bohr model). In 1928, George Gamow proposed the liquid-drop model, which became essential to understanding the physics of fission. In 1896, Henri Becquerel had found, and Marie Curie named, radioactivity. In 1900, Rutherford and Frederick Soddy, investigating the radioactive gas emanating from thorium, "conveyed the tremendous and inevitable conclusion that the element thorium was slowly and spontaneously transmuting itself into argon gas!" In 1919, following up on an earlier anomaly Ernest Marsden noted in 1915, Rutherford attempted to "break up the atom." Rutherford was able to accomplish the first artificial transmutation of nitrogen into oxygen, using alpha particles directed at nitrogen 14N + α → 17O + p. Rutherford stated, "...we must conclude that the nitrogen atom is disintegrated," while the newspapers stated he had split the atom.
Sources: en.wikipedia.org
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.
It has not been approved by major regulatory agencies for any therapeutic indication. Material sold under this name is typically distributed for laboratory research only. Clinical use is not supported by large controlled trials.
Early human studies of the albumin-binding form reported circulation half-lives on the order of several days. The value depends on assay method and study design. Estimates for the form without the binding moiety are considerably shorter.
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.